Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Therapeutic Drug Monitoring of Voriconazole in Children with Hematologic Malignancy and Invasive Fungal Infections: An RCT from a Tertiary Care Centre in India

Author(s): Neha Sharad, Gagandeep Singh*, Immaculata Xess, Reshu Agarwal, Tulika Seth, K.H. Reeta and Sweta Kothari

Volume 23, Issue 4, 2023

Published on: 21 November, 2023

Page: [285 - 292] Pages: 8

DOI: 10.2174/011871529X245299231102055046

Price: $65

Abstract

Introduction: Voriconazole is a triazole anti-fungal with non-linear kinetics and a narrow therapeutic range. The objective of our study was to monitor the voriconazole serum levels in children with hematological malignancy and clinically suspected invasive fungal infections.

Methods: The study was a prospective, randomized controlled trial conducted from June 2016 to December 2017. All children who had haematologic malignancies with clinically suspected invasive fungal infections and received voriconazole as the only anti-fungal were included in the study. The children were randomly allotted into two groups; one was the group that underwent TDM, and the other, TDM, was not done. Bioassay was the method employed for TDM. The trough levels were evaluated on a sample obtained on the fifth day of starting the drug. The institute's ethics committee approved the study.

Result: A total of 30 children were included in the study: 15 in the TDM group and 15 in the non-TDM group. The most common underlying malignancy was AML. Neutropenia due to chemotherapy sessions was these patients' most common risk factor. A favorable outcome was seen in 13/15 (86.7%) in the TDM group and 11/15 in the non-TDM group (73.3%).

Conclusion: Only five out of 15 (33.3%) children had voriconazole serum levels within the therapeutic range. Alterations in dose had to be done in the remaining to achieve the recommended serum levels. Thus, we recommend TDM for all children of hematologic malignancy receiving voriconazole for better management. Our findings also revealed that children with AML had lower than recommended levels of voriconazole on TDM evaluation, whereas those with ALL had normal to elevated levels of voriconazole.

Keywords: Voriconazole, TDM, children, IFIs, hematologic malignancy, aspergillus.

« Previous Next »
Graphical Abstract

[1]
Montagna, M.T.; Giglio, O.D.; Napoli, C.; Lovero, G.; Caggiano, G.; Delia, M.; Pastore, D.; Santoro, N.; Specchia, G. Invasive fungal infections in patients with hematologic malignancies (aurora project): Lights and shadows during 18-months surveillance. Int. J. Mol. Sci., 2012, 13(1), 774-787.
[http://dx.doi.org/10.3390/ijms13010774] [PMID: 22312285]
[2]
Pagano, L.; Caira, M.; Candoni, A.; Offidani, M.; Fianchi, L.; Martino, B.; Pastore, D.; Picardi, M.; Bonini, A.; Chierichini, A.; Fanci, R.; Caramatti, C.; Invernizzi, R.; Mattei, D.; Mitra, M.E.; Melillo, L.; Aversa, F.; Van Lint, M.T.; Falcucci, P.; Valentini, C.G.; Girmenia, C.; Nosari, A. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica, 2006, 91(8), 1068-1075.
[PMID: 16885047]
[3]
Lipp, H.P. Antifungal agents – clinical pharmacokinetics and drug interactions. Mycoses, 2008, 51(s1)(Suppl. 1), 7-18.
[http://dx.doi.org/10.1111/j.1439-0507.2008.01523.x] [PMID: 18471156]
[4]
Maertens, J.; Meersseman, W.; Van Bleyenbergh, P. New therapies for fungal pneumonia. Curr. Opin. Infect. Dis., 2009, 22(2), 183-190.
[http://dx.doi.org/10.1097/QCO.0b013e328328cfff] [PMID: 19276884]
[5]
Lamoureux, F.; Duflot, T.; Woillard, J.B.; Metsu, D.; Pereira, T.; Compagnon, P.; Morisse-Pradier, H.; El Kholy, M.; Thiberville, L.; Stojanova, J.; Thuillez, C. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int. J. Antimicrob. Agents, 2016, 47(2), 124-131.
[http://dx.doi.org/10.1016/j.ijantimicag.2015.12.003] [PMID: 26775563]
[6]
Touw, D.J.; Neef, C.; Thomson, A.H.; Vinks, A.A. Cost-effectiveness of therapeutic drug monitoring: A systematic review. Ther. Drug Monit., 2005, 27(1), 10-17.
[http://dx.doi.org/10.1097/00007691-200502000-00004] [PMID: 15665740]
[7]
Hope, W.W.; Billaud, E.M.; Lestner, J.; Denning, D.W. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis., 2008, 21(6), 580-586.
[http://dx.doi.org/10.1097/QCO.0b013e3283184611] [PMID: 18978525]
[8]
Ashbee, H.R.; Barnes, R.A.; Johnson, E.M.; Richardson, M.D.; Gorton, R.; Hope, W.W. Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother., 2014, 69(5), 1162-1176.
[http://dx.doi.org/10.1093/jac/dkt508] [PMID: 24379304]
[9]
Brüggemann, R.J.M.; Antonius, T.; Heijst, A.; Hoogerbrugge, P.M.; Burger, D.M.; Warris, A. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. Ther. Drug Monit., 2008, 30(6), 643-646.
[http://dx.doi.org/10.1097/FTD.0b013e3181898b0c] [PMID: 19057370]
[10]
Smith, J.; Andes, D. Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit., 2008, 30(2), 167-172.
[http://dx.doi.org/10.1097/FTD.0b013e318167d0e0] [PMID: 18367976]
[11]
Caroline Moore. Bioassay for determining voriconazole levels in blood; , 2010. Available From: [https://www.aspergillus.org.uk/lab_protocols/bioassay-for-determi ning-voriconazole-levels-in-blood/
[12]
Soler-Palacín, P.; Frick, M.A.; Martín-Nalda, A.; Lanaspa, M.; Pou, L.; Roselló, E.; Diaz de Heredia, C.; Figueras, C. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study. J. Antimicrob. Chemother., 2012, 67(3), 700-706.
[http://dx.doi.org/10.1093/jac/dkr517] [PMID: 22190607]
[13]
Pascual, A.; Calandra, T.; Bolay, S.; Buclin, T.; Bille, J.; Marchetti, O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis., 2008, 46(2), 201-211.
[http://dx.doi.org/10.1086/524669] [PMID: 18171251]
[14]
Park, W.B.; Kim, N.H.; Kim, K.H.; Lee, S.H.; Nam, W.S.; Yoon, S.H.; Song, K.H.; Choe, P.G.; Kim, N.J.; Jang, I.J.; Oh, M.; Yu, K.S. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. Clin. Infect. Dis., 2012, 55(8), 1080-1087.
[http://dx.doi.org/10.1093/cid/cis599] [PMID: 22761409]
[15]
Yi, W.M.; Schoeppler, K.E.; Jaeger, J.; Mueller, S.W.; MacLaren, R.; Fish, D.N.; Kiser, T.H. Voriconazole and posaconazole therapeutic drug monitoring: A retrospective study. Ann. Clin. Microbiol. Antimicrob., 2017, 16(1), 60.
[http://dx.doi.org/10.1186/s12941-017-0235-8] [PMID: 28893246]
[16]
Valle-T-Figueras, J.M.; Renedo Miró, B.; Benítez Carabante, M.I.; Díaz-de-Heredia, C.; Vima Bofarull, J.; Mendoza-Palomar, N.; Martín-Gómez, M.T.; Soler-Palacín, P. Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment. J. Fungi (Basel), 2021, 7(6), 456.
[http://dx.doi.org/10.3390/jof7060456] [PMID: 34200506]
[17]
Steinmann, J.; Huelsewede, J.; Buer, J.; Rath, P.M. Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. Mycoses, 2011, 54(5), e421-e428.
[http://dx.doi.org/10.1111/j.1439-0507.2010.01938.x] [PMID: 20667002]
[18]
Siopi, M.; Neroutsos, E.; Zisaki, K.; Gamaletsou, M.; Pirounaki, M.; Tsirigotis, P.; Sipsas, N.; Dokoumetzidis, A.; Goussetis, E.; Zerva, L.; Valsami, G.; Meletiadis, J. Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins. Antimicrob. Agents Chemother., 2016, 60(1), 632-636.
[http://dx.doi.org/10.1128/AAC.01688-15] [PMID: 26503649]
[19]
Costa, M.C.N.; Barden, A.T.; Andrade, J.M.M.; Oppe, T.P.; Schapoval, E.E.S. Quantitative evaluation of besifloxacin ophthalmic suspension by HPLC, application to bioassay method and cytotoxicity studies. Talanta, 2014, 119, 367-374.
[http://dx.doi.org/10.1016/j.talanta.2013.10.051] [PMID: 24401427]
[20]
Lin, G.L.; Chang, H.H.; Lu, C.Y.; Chen, C.M.; Lu, M.Y.; Lee, P.I.; Jou, S.T.; Yang, Y.L.; Huang, L.M.; Chang, L.Y. Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan. J. Microbiol. Immunol. Infect., 2018, 51(2), 251-259.
[http://dx.doi.org/10.1016/j.jmii.2016.08.011] [PMID: 28089099]
[21]
Keevil, B.G.; Newman, S.; Lockhart, S.; Howard, S.J.; Moore, C.B.; Denning, D.W. Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther. Drug Monit., 2004, 26(6), 650-657.
[http://dx.doi.org/10.1097/00007691-200412000-00011] [PMID: 15570190]
[22]
Kazakou, N.; Vyzantiadis, T.A.; Gambeta, A.; Vasileiou, E.; Tsotridou, E.; Kotsos, D.; Giantsidi, A.; Saranti, A.; Palabougiouki, M.; Ioannidou, M.; Hatzipantelis, E.; Tragiannidis, A. Invasive fungal infections in a pediatric hematology-oncology department: A 16-year retrospective study. Curr. Med. Mycol., 2020, 6(2), 37-42.
[http://dx.doi.org/10.18502/cmm.6.2.2840] [PMID: 33628980]
[23]
Sezgin Evim, M.; Tüfekçi, Ö.; Baytan, B.; Ören, H.; Çelebi, S.; Ener, B.; Üstün Elmas, K.; Yılmaz, Ş.; Erdem, M.; Hacımustafaoğlu, M.K.; Güneş, A.M. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis. Turk. J. Haematol., 2022, 39(2), 94-102.
[PMID: 34792308]
[24]
Hsu, L.Y.; Lee, D.G.; Yeh, S.P.; Bhurani, D.; Khanh, B.Q.; Low, C.Y.; Norasetthada, L.; Chan, T.; Kwong, Y.L.; Vaid, A.K.; Alejandria, I.; Mendoza, M.; Chen, C.Y.; Johnson, A.; Tan, T.Y. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: A prospective observational study. Clin. Microbiol. Infect., 2015, 21(6), 594.e7-594.e11.
[http://dx.doi.org/10.1016/j.cmi.2015.02.019] [PMID: 25749561]
[25]
Tang, J.L.; Kung, H.C.; Lei, W.C.; Yao, M.; Wu, U.I.; Hsu, S.C.; Lin, C.T.; Li, C.C.; Wu, S.J.; Hou, H.A.; Chou, W.C.; Huang, S.Y.; Tsay, W.; Chen, Y.C.; Chen, Y.C.; Chang, S.C.; Ko, B.S.; Tien, H.F. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS One, 2015, 10(6), e0128410.
[http://dx.doi.org/10.1371/journal.pone.0128410] [PMID: 26061179]
[26]
R, M.; M, S. Invasive fungal infections in hematology: New trends. Ann. Hematol., 2002, 81(5), 233-243.
[http://dx.doi.org/10.1007/s00277-002-0466-3] [PMID: 12029531]
[27]
Ueda, K.; Nannya, Y.; Kumano, K.; Hangaishi, A.; Takahashi, T.; Imai, Y.; Kurokawa, M. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int. J. Hematol., 2009, 89(5), 592-599.
[http://dx.doi.org/10.1007/s12185-009-0296-3] [PMID: 19340528]
[28]
Smith, J.; Safdar, N.; Knasinski, V.; Simmons, W.; Bhavnani, S.M.; Ambrose, P.G.; Andes, D. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother., 2006, 50(4), 1570-1572.
[http://dx.doi.org/10.1128/AAC.50.4.1570-1572.2006] [PMID: 16569888]
[29]
Trifilio, S.; Singhal, S.; Williams, S.; Frankfurt, O.; Gordon, L.; Evens, A.; Winter, J.; Tallman, M.; Pi, J.; Mehta, J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant., 2007, 40(5), 451-456.
[http://dx.doi.org/10.1038/sj.bmt.1705754] [PMID: 17589527]
[30]
Denning, D.W.; Ribaud, P.; Milpied, N.; Caillot, D.; Herbrecht, R.; Thiel, E.; Haas, A.; Ruhnke, M.; Lode, H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis., 2002, 34(5), 563-571.
[http://dx.doi.org/10.1086/324620] [PMID: 11807679]
[31]
Boyd, A.E.; Modi, S.; Howard, S.J.; Moore, C.B.; Keevil, B.G.; Denning, D.W. Adverse reactions to voriconazole. Clin. Infect. Dis., 2004, 39(8), 1241-1244.
[http://dx.doi.org/10.1086/424662] [PMID: 15486850]
[32]
Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Körholz, C.; Preiss, R. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother., 2010, 54(8), 3225-3232.
[http://dx.doi.org/10.1128/AAC.01731-09] [PMID: 20547816]
[33]
Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother., 2010, 54(10), 4116-4123.
[http://dx.doi.org/10.1128/AAC.00896-10] [PMID: 20660687]

Rights & Permissions Print Cite
Article Metrics
14
3
© 2024 Bentham Science Publishers | Privacy Policy